Evoke Pharma Change in Accounts Receivable 2012-2024 | EVOK
Evoke Pharma change in accounts receivable from 2012 to 2024. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Evoke Pharma Annual Change in Accounts Receivable
(Millions of US $) |
| 2024 |
$-2 |
| 2023 |
$0 |
| 2022 |
$0 |
| 2021 |
$0 |
| 2020 |
$N/A |
| 2019 |
$N/A |
| 2018 |
$N/A |
| 2017 |
$N/A |
| 2016 |
$N/A |
| 2015 |
$N/A |
| 2014 |
$N/A |
| 2013 |
$N/A |
| 2012 |
$N/A |
| 2011 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.007B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
